Developer docs
API playgroundTry for free, no card

Search company profiles

Nexalin Technology

Full company profile

uuid00008pe

Namestring
Nexalin Technology
Legal namestring
Nexalin Technology Inc
Websiteurl
nexalin.com
Company typeenum
Public
Founded yearint
2010
Descriptiontext

Nexalin Technology is a Houston-based, NASDAQ-listed (NXL) medical device company founded in 2010 that develops non-invasive transcranial electrical stimulation equipment for the treatment of anxiety, depression, insomnia, and related neurological conditions. Its core technology is the proprietary DIFS (Deep Intracranial Frequency Stimulation) platform, which delivers a 15 mA, 77.5 Hz alternating current waveform designed to interact with deep midbrain structures and normalize brain neurochemistry without medication. The product portfolio consists of the Gen-2 SYNC clinical console, which has received regulatory approvals in China, Brazil, Oman, and Israel, and the Gen-3 HALO Clarity headset, a home-use device currently in a 160-participant pivotal FDA trial targeting moderate-to-severe insomnia via the De Novo pathway.

The company monetizes through three streams: one-time device sales of Gen-2 SYNC hardware in approved international markets, an exclusive distribution partnership with Carmi Masha Technologies in Israel, and a subscription-based virtual clinic model delivered via the AI-designed NeuroCare platform integrated with the recently acquired PONM digital health system. Reported clinical outcomes from trials conducted at the University of São Paulo include a 77.8% anxiety response rate and 66.7% depression response/remission rate, and a U.S. Patent (No. 12,629,519) provides intellectual property protection through 2042.

Nexalin is at an early commercialization stage: it employs 1-10 people, reports approximately $280,000 in LTM revenue as of June 2026, and has raised roughly $11.5 million since 2024 through two underwritten public offerings (Maxim Group LLC) plus a $1.3 million stock-funded acquisition of PONM, Inc. The company's strategic priorities are advancing HALO Clarity through FDA clearance, expanding the NeuroCare virtual clinic subscription model, and pursuing adjacent indications including Alzheimer's disease, TBI, and PTSD via academic and VA clinical partnerships.

Short descriptiontext

Nexalin Technology is a Houston-based, NASDAQ-listed medical device company developing non-invasive transcranial neurostimulation devices (Gen-2 SYNC and Gen-3 HALO Clarity) using its proprietary DIFS platform to treat anxiety, depression, insomnia, and related neurological conditions through subscription and device sales.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurostimulation medical devices, transcranial electrical stimulation, non-invasive brain stimulation, mental health treatment devices, virtual clinic platform
Industry3 codes
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAKAIAA
General Neurology
SECONDARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Neurostimulation Medical Devices
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Virtual Clinic Subscription
TypeSubscription Recurring
Description

Subscription-based business model through NeuroCare virtual clinic platform. Patients pay for ongoing neurostimulation treatments administered at home under physician supervision. Designed for scalable, recurring revenue from global brain health markets.

quiverquant.com
2Device Sales
TypeHardware Sales
Description

Direct sales of Gen-2 SYNC neurostimulation devices in approved international markets (China, Brazil, Oman, Israel). One-time device purchases supplemented by ongoing treatment delivery.

globenewswire.com
3Distribution/ Licensing
TypeLicensing Royalties
Description

Revenue through exclusive distribution agreements with regional partners like Carmi Masha Technologies Ltd. in Israel. Company provides products while distributors handle local commercialization.

globenewswire.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1HALO Clarity
Description

Gen-3 HALO neurostimulation headset for treating insomnia and other brain health conditions using Deep Intracranial Frequency Stimulation technology

stocktitan.net
+3 more records
Core offering1 text field

Nexalin Technology develops and commercializes non-invasive transcranial neurostimulation devices based on its proprietary Deep Intracranial Frequency Stimulation (DIFS) platform, delivering 15 mA, 77.5 Hz frequency-based waveforms to treat anxiety, depression, insomnia, traumatic brain injury, PTSD, and Alzheimer's disease. The company sells its Gen-2 SYNC devices in approved international markets and operates an AI-powered NeuroCare virtual clinic platform that enables physicians to remotely prescribe and monitor home-based neurostimulation treatments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 77.8% anxiety response rate at end of treatment, maintained at 8-week follow-up
+4 more records
Product overview1 text field

Nexalin Technology offers a unified neurostimulation platform centered on its proprietary DIFS™ (Deep Intracranial Frequency Stimulation) technology. The product portfolio consists of Gen-2 SYNC and Gen-3 HALO Clarity neurostimulation devices that deliver the DIFS waveform for mental health treatment, supported by the AI-designed NeuroCare virtual clinic platform for remote patient monitoring and care management. The recently acquired PONM digital health platform integrates with HALO Clarity and NeuroCare to provide remote patient monitoring, clinical data capture, EHR functionality, and virtual clinic management. The Gen-2 SYNC device has regulatory approvals in China, Brazil, Oman, and Israel, while Gen-3 HALO Clarity is advancing through FDA De Novo regulatory pathway for insomnia treatment in the US.

Product and service4 records
1DIFS (Deep Intracranial Frequency Stimulation) Platform
CategoryCore Technology Platform
Description

Core neurostimulation technology platform using 15 mA, 77.5 Hz frequency-based waveforms that interact with deep centers of the midbrain to normalize brain neurochemicals for treatment of anxiety, depression, insomnia, and other neurological conditions. Sold as the technological foundation underlying Nexalin's hardware devices.

2Gen-2 SYNC Neurostimulation Device
CategoryMedical Device
Description

Second-generation medical device delivering DIFS technology, designed for clinical setting use to treat mental health conditions including depression and insomnia. Regulatory approved in China, Brazil, Oman, and Israel.

3Gen-3 HALO Clarity Headset
CategoryMedical Device
Description

Third-generation non-invasive home-use headset for delivering DIFS neurostimulation treatment under physician supervision, integrated with the NeuroCare virtual clinic platform for remote patient monitoring. Advancing through FDA De Novo regulatory pathway for insomnia treatment in the US.

4NeuroCare Virtual Clinic
CategoryDigital Health Software
Description

AI-designed subscription-based virtual clinic platform enabling remote physician-monitored neurotherapy for brain health conditions including Alzheimer's, mood disorders, TBI, and PTSD. Provides remote patient monitoring, clinical data capture, EHR functionality, and analytics.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-19
Description

Strategic partnership following Nexalin's $1.3 million acquisition of PONM digital health platform. GreenLight Ventures became an equity holder in Nexalin and provides ongoing development services including engineering, regulatory, and commercial capabilities. The PONM platform supports HALO Clarity program and NeuroCare virtual clinic.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-04-22
Description

Accountable Research Organization partnership for execution of pivotal FDA clinical trial for HALO Clarity insomnia treatment. Lindus Health providing full-scope trial execution from protocol finalization through database lock for the 160-participant randomized sham-controlled study.

3Professor Yi Tang, Xuanwu Hospital (China)
Strategic tierRegionalTypeStrategic or Co-development PartnerAnnounced on2026-04-15
Description

Collaboration with Professor Yi Tang from Xuanwu Hospital in China for Alzheimer's disease clinical program. Professor Tang brings extensive real-world clinical experience from ongoing studies using Nexalin's non-invasive neurostimulation device on Alzheimer's patients.

stocktitan.net
4University of California, San Diego
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-05
Description

Clinical research partnership for military TBI/PTSD study using HALO neurostimulation headset. PONM digital health platform deployed at UCSD supporting remote patient monitoring, clinical data capture, and virtual care workflows for the clinical trial program.

biospace.com
5Carmi Masha Technologies Ltd.
Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-11-13
Description

Exclusive distribution agreement for marketing Gen-2 SYNC neurostimulation device in Israel following regulatory approval. Partnership aims to expand access to Nexalin's non-invasive mental health treatment and explore future applications in the Israeli market.

globenewswire.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

U.S.-listed developer of transcranial magnetic stimulation (NeuroStar) systems for major depressive disorder. Directly comparable to Nexalin because it competes in non-invasive neuromodulation for mental-health indications, including anxiety and depression, with similar provider-channel economics and FDA-cleared status.

TypeDirect peer
Description

Israel-based developer of Deep TMS systems approved for depression, OCD, and smoking addiction. Highly comparable to Nexalin given its non-invasive neurostimulation modality, mental-health indications, and presence in Israel — the same market where Nexalin just received Gen-2 SYNC clearance.

TypeDirect peer
Description

Developer of non-invasive vagus nerve stimulation (gammaCore) devices, primarily for migraine and headache but expanding into broader neurology. Comparable as a small-cap, non-invasive neurostimulation company pursuing adjacent neurological indications through a similar provider-channel model.

TypeDirect peer
Description

Developer of the RNS System, a closed-loop responsive neurostimulation device for refractory epilepsy. Comparable as a small-cap neurostimulation pure-play pursuing neurological indications, although NeuroPace is invasive/implanted whereas Nexalin is non-invasive.

TypeBroad incumbent
Description

Larger diversified medical-device company with a Vagus Nerve Stimulation (VNS) Therapy system approved for drug-resistant epilepsy and treatment-resistant depression. Comparable as an established neuromodulation incumbent in mental-health indications, though it operates a broader device portfolio beyond neurostimulation.

6Axonics
TypeBroad incumbent
Description

Public neuromodulation company focused on sacral and pudendal nerve stimulation for incontinence and overactive bladder. Comparable as a small-to-mid-cap neurostimulation device company with FDA-cleared products, although its primary indications differ from Nexalin's CNS focus.

TypeEmerging player
Description

Privately-held developer of transcranial direct current stimulation (tDCS) and transcranial alternating current stimulation (tACS) platforms for research and clinical applications. Closely comparable to Nexalin's DIFS technology on modality and waveform category, though Soterix is primarily research-focused and not a direct commercial competitor.

TypeEmerging player
Description

Digital therapeutics company commercializing Sleepio for insomnia and Daylight for anxiety. Comparable to the NeuroCare virtual-clinic / digital-therapeutic layer of Nexalin's offering — same indications (insomnia, anxiety), same digital-delivery model — although Big Health is software-only rather than device-anchored.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nexalin Technology

Neurostimulation Medical Devicesnexalin.com

Nexalin Technology is a Houston-based, NASDAQ-listed medical device company developing non-invasive transcranial neurostimulation devices (Gen-2 SYNC and Gen-3 HALO Clarity) using its proprietary DIFS platform to treat anxiety, depression, insomnia, and related neurological conditions through subscription and device sales.

What Nexalin Technology does

Nexalin Technology is a Houston-based, NASDAQ-listed (NXL) medical device company founded in 2010 that develops non-invasive transcranial electrical stimulation equipment for the treatment of anxiety, depression, insomnia, and related neurological conditions. Its core technology is the proprietary DIFS (Deep Intracranial Frequency Stimulation) platform, which delivers a 15 mA, 77.5 Hz alternating current waveform designed to interact with deep midbrain structures and normalize brain neurochemistry without medication. The product portfolio consists of the Gen-2 SYNC clinical console, which has received regulatory approvals in China, Brazil, Oman, and Israel, and the Gen-3 HALO Clarity headset, a home-use device currently in a 160-participant pivotal FDA trial targeting moderate-to-severe insomnia via the De Novo pathway.

The company monetizes through three streams: one-time device sales of Gen-2 SYNC hardware in approved international markets, an exclusive distribution partnership with Carmi Masha Technologies in Israel, and a subscription-based virtual clinic model delivered via the AI-designed NeuroCare platform integrated with the recently acquired PONM digital health system. Reported clinical outcomes from trials conducted at the University of São Paulo include a 77.8% anxiety response rate and 66.7% depression response/remission rate, and a U.S. Patent (No. 12,629,519) provides intellectual property protection through 2042.

Nexalin is at an early commercialization stage: it employs 1-10 people, reports approximately $280,000 in LTM revenue as of June 2026, and has raised roughly $11.5 million since 2024 through two underwritten public offerings (Maxim Group LLC) plus a $1.3 million stock-funded acquisition of PONM, Inc. The company's strategic priorities are advancing HALO Clarity through FDA clearance, expanding the NeuroCare virtual clinic subscription model, and pursuing adjacent indications including Alzheimer's disease, TBI, and PTSD via academic and VA clinical partnerships.

Nexalin Technology firmographics

Firmographics
Name
Nexalin Technology
Legal name
Nexalin Technology Inc
Website
https://nexalin.com
Company type
Public
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
Nexalin Technology is a Houston-based, NASDAQ-listed medical device company developing non-invasive transcranial neurostimulation devices (Gen-2 SYNC and Gen-3 HALO Clarity) using its proprietary DIFS platform to treat anxiety, depression, insomnia, and related neurological conditions through subscription and device sales.
Ownership category
akta.pro rank

Nexalin Technology industry classification

Industry
Product category
Neurostimulation Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAKAIAA
General Neurology
SECONDARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Neurostimulation medical devices
  • Transcranial electrical stimulation
  • Non-invasive brain stimulation
  • Mental health treatment devices
  • Virtual clinic platform

Where Nexalin Technology is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Nexalin Technology business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Virtual Clinic Subscription: Subscription-based business model through NeuroCare virtual clinic platform. Patients pay for ongoing neurostimulation treatments administered at home under physician supervision. Designed for scalable, recurring revenue from global brain health markets.
  2. Device Sales: Direct sales of Gen-2 SYNC neurostimulation devices in approved international markets (China, Brazil, Oman, Israel). One-time device purchases supplemented by ongoing treatment delivery.
  3. Distribution/ Licensing: Revenue through exclusive distribution agreements with regional partners like Carmi Masha Technologies Ltd. in Israel. Company provides products while distributors handle local commercialization.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels3 records

Nexalin Technology product offering

Product offering

Core offering

Nexalin Technology develops and commercializes non-invasive transcranial neurostimulation devices based on its proprietary Deep Intracranial Frequency Stimulation (DIFS) platform, delivering 15 mA, 77.5 Hz frequency-based waveforms to treat anxiety, depression, insomnia, traumatic brain injury, PTSD, and Alzheimer's disease. The company sells its Gen-2 SYNC devices in approved international markets and operates an AI-powered NeuroCare virtual clinic platform that enables physicians to remotely prescribe and monitor home-based neurostimulation treatments.

Product overview

Nexalin Technology offers a unified neurostimulation platform centered on its proprietary DIFS™ (Deep Intracranial Frequency Stimulation) technology. The product portfolio consists of Gen-2 SYNC and Gen-3 HALO Clarity neurostimulation devices that deliver the DIFS waveform for mental health treatment, supported by the AI-designed NeuroCare virtual clinic platform for remote patient monitoring and care management. The recently acquired PONM digital health platform integrates with HALO Clarity and NeuroCare to provide remote patient monitoring, clinical data capture, EHR functionality, and virtual clinic management. The Gen-2 SYNC device has regulatory approvals in China, Brazil, Oman, and Israel, while Gen-3 HALO Clarity is advancing through FDA De Novo regulatory pathway for insomnia treatment in the US.

Differentiator

Problem solved

Functional benefit

Brands

  • HALO Clarity: Gen-3 HALO neurostimulation headset for treating insomnia and other brain health conditions using Deep Intracranial Frequency Stimulation technology
  • NeuroCare
  • DIFS
  • Gen-2 SYNC

Products and services

  • DIFS (Deep Intracranial Frequency Stimulation) Platform Core neurostimulation technology platform using 15 mA, 77.5 Hz frequency-based waveforms that interact with deep centers of the midbrain to normalize brain neurochemicals for treatment of anxiety, depression, insomnia, and other neurological conditions. Sold as the technological foundation underlying Nexalin's hardware devices.
  • Gen-2 SYNC Neurostimulation Device Second-generation medical device delivering DIFS technology, designed for clinical setting use to treat mental health conditions including depression and insomnia. Regulatory approved in China, Brazil, Oman, and Israel.
  • Gen-3 HALO Clarity Headset Third-generation non-invasive home-use headset for delivering DIFS neurostimulation treatment under physician supervision, integrated with the NeuroCare virtual clinic platform for remote patient monitoring. Advancing through FDA De Novo regulatory pathway for insomnia treatment in the US.
  • NeuroCare Virtual Clinic AI-designed subscription-based virtual clinic platform enabling remote physician-monitored neurotherapy for brain health conditions including Alzheimer's, mood disorders, TBI, and PTSD. Provides remote patient monitoring, clinical data capture, EHR functionality, and analytics.

Quantifiable outcome

  • 77.8% anxiety response rate at end of treatment, maintained at 8-week follow-up
  • +4 more outcomes

Companies that use Nexalin Technology

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Nexalin Technology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Nexalin Technology partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and regional.

  • GreenLight Ventures LLCcoreStrategic or Co-development Partner · 19 May 2026Strategic partnership following Nexalin's $1.3 million acquisition of PONM digital health platform. GreenLight Ventures became an equity holder in Nexalin and provides ongoing development services including engineering, regulatory, and commercial capabilities. The PONM platform supports HALO Clarity program and NeuroCare virtual clinic.
  • Lindus HealthcoreImplementation/ SI/ Consulting Partner · 22 April 2026Accountable Research Organization partnership for execution of pivotal FDA clinical trial for HALO Clarity insomnia treatment. Lindus Health providing full-scope trial execution from protocol finalization through database lock for the 160-participant randomized sham-controlled study.
  • Professor Yi Tang, Xuanwu Hospital (China)regionalStrategic or Co-development Partner · 15 April 2026Collaboration with Professor Yi Tang from Xuanwu Hospital in China for Alzheimer's disease clinical program. Professor Tang brings extensive real-world clinical experience from ongoing studies using Nexalin's non-invasive neurostimulation device on Alzheimer's patients.
  • University of California, San DiegocoreStrategic or Co-development Partner · 5 February 2026Clinical research partnership for military TBI/PTSD study using HALO neurostimulation headset. PONM digital health platform deployed at UCSD supporting remote patient monitoring, clinical data capture, and virtual care workflows for the clinical trial program.
  • Carmi Masha Technologies Ltd.regionalChannel Partner/ Reseller/ Distributor · 13 November 2025Exclusive distribution agreement for marketing Gen-2 SYNC neurostimulation device in Israel following regulatory approval. Partnership aims to expand access to Nexalin's non-invasive mental health treatment and explore future applications in the Israeli market.

Scale indicators7 records

Recent moves6 records

Expansion highlights8 records

Nexalin Technology competitors and assessment

Company assessment

Direct peers

  • Neuronetics: U.S.-listed developer of transcranial magnetic stimulation (NeuroStar) systems for major depressive disorder. Directly comparable to Nexalin because it competes in non-invasive neuromodulation for mental-health indications, including anxiety and depression, with similar provider-channel economics and FDA-cleared status.
  • Brainsway: Israel-based developer of Deep TMS systems approved for depression, OCD, and smoking addiction. Highly comparable to Nexalin given its non-invasive neurostimulation modality, mental-health indications, and presence in Israel — the same market where Nexalin just received Gen-2 SYNC clearance.
  • Electrocore: Developer of non-invasive vagus nerve stimulation (gammaCore) devices, primarily for migraine and headache but expanding into broader neurology. Comparable as a small-cap, non-invasive neurostimulation company pursuing adjacent neurological indications through a similar provider-channel model.
  • NeuroPace: Developer of the RNS System, a closed-loop responsive neurostimulation device for refractory epilepsy. Comparable as a small-cap neurostimulation pure-play pursuing neurological indications, although NeuroPace is invasive/implanted whereas Nexalin is non-invasive.

Broad incumbents

  • LivaNova: Larger diversified medical-device company with a Vagus Nerve Stimulation (VNS) Therapy system approved for drug-resistant epilepsy and treatment-resistant depression. Comparable as an established neuromodulation incumbent in mental-health indications, though it operates a broader device portfolio beyond neurostimulation.
  • Axonics: Public neuromodulation company focused on sacral and pudendal nerve stimulation for incontinence and overactive bladder. Comparable as a small-to-mid-cap neurostimulation device company with FDA-cleared products, although its primary indications differ from Nexalin's CNS focus.

Emerging players

  • Soterix Medical: Privately-held developer of transcranial direct current stimulation (tDCS) and transcranial alternating current stimulation (tACS) platforms for research and clinical applications. Closely comparable to Nexalin's DIFS technology on modality and waveform category, though Soterix is primarily research-focused and not a direct commercial competitor.
  • Big Health: Digital therapeutics company commercializing Sleepio for insomnia and Daylight for anxiety. Comparable to the NeuroCare virtual-clinic / digital-therapeutic layer of Nexalin's offering — same indications (insomnia, anxiety), same digital-delivery model — although Big Health is software-only rather than device-anchored.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Nexalin Technology social profiles

Digital presence

Nexalin Technology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nexalin Technology leadership team

Management profile

Number of profiles

Profiles6 records

Nexalin Technology subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Nexalin Technology funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nexalin Technology M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nexalin Technology

What does Nexalin Technology do?

Nexalin Technology develops and commercializes non-invasive transcranial neurostimulation devices based on its proprietary Deep Intracranial Frequency Stimulation (DIFS) platform, delivering 15 mA, 77.5 Hz frequency-based waveforms to treat anxiety, depression, insomnia, traumatic brain injury, PTSD, and Alzheimer's disease. The company sells its Gen-2 SYNC devices in approved international markets and operates an AI-powered NeuroCare virtual clinic platform that enables physicians to remotely prescribe and monitor home-based neurostimulation treatments.

Is Nexalin Technology a public or private company?

Nexalin Technology is a public company. It is classified as public and is currently operating.

When was Nexalin Technology founded?

Nexalin Technology was founded in 2010. It employs 11 to 50 people.

Where is Nexalin Technology based?

Nexalin Technology is headquartered in Houston, United States, in the North America region.

How does Nexalin Technology make money?

Three revenue lines are on record. Virtual Clinic Subscription is the primary driver. The others are device Sales and distribution/ Licensing.

Who are Nexalin Technology's main competitors?

Direct peers on record are Neuronetics, Brainsway, Electrocore and NeuroPace. Broad incumbents are LivaNova and Axonics. Emerging players are Soterix Medical and Big Health.

Does Nexalin Technology have an API?

No public API is recorded for Nexalin Technology.

What industry is Nexalin Technology in?

Nexalin Technology's product category is Neurostimulation Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAKAIAA, General Neurology. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsNexalin Technology, Inc. (NASDAQ:NXL) Stock Short Interest Jumps 180.7%Short interest in Nexalin Technology surged 180.7% to 12,581 shares as of October 30th. PEAK6 LLC bought 240,210 shares, and analysts rate the stock a consensus "Reduce". The company reported a loss of $3.43 per share for the quarter.American Banking and Market NewsNexalin Technology (NXL) Set to Release Quarterly Earnings on FridayNexalin Technology is set to release its Q3 2026 earnings on Friday, November 13th. Analysts expect a loss of $2.91 per share and revenue of $0.07 million. The company's consensus rating is 'Reduce'.The future of tradingNexalin Device Improves Sleep Quality in Mild Alzheimer’s Patients in Sham-Controlled StudyNexalin Technology published TRANSFORM-AD results in the Journal of Alzheimer's Disease, showing its brain-stimulation device significantly improved sleep in mild Alzheimer's patients. The randomized, blinded trial compared the Gen-2 SYNC device with sham treatment, with no serious adverse events. Benefits for anxiety, depression, and quality of life were inconclusive, and a U.S. pilot study is planned.American Banking and Market NewsSiBone (NASDAQ:SIBN) and Nexalin Technology (NASDAQ:NXL) Financial ContrastSiBone and Nexalin Technology are compared on financial metrics, with SiBone favored on 9 of 14 factors. SiBone has a lower P/E ratio, higher institutional ownership, and a stronger analyst consensus with a $24.17 target price. Nexalin Technology shows higher earnings but lower revenue and higher volatility.Markets DailyHead to Head Survey: Nexalin Technology (NASDAQ:NXL) and SiBone (NASDAQ:SIBN)SiBone and Nexalin Technology are compared on ratings, ownership, risk, and valuation. SiBone has a stronger consensus rating, higher institutional ownership, and lower volatility, beating Nexalin on 9 of 14 factors. Analysts see a 26.28% upside in SiBone's price target.American Banking and Market NewsContrasting Enovis (NYSE:ENOV) & Nexalin Technology (NASDAQ:NXL)Enovis and Nexalin Technology are compared on valuation, profitability, and institutional ownership. Enovis has a stronger consensus rating, lower beta, and higher institutional ownership, beating Nexalin on 8 of 14 factors. Analysts see Enovis with a consensus price target of $39.50, implying 110.24% upside.American Banking and Market NewsTop Medical Stocks To Watch Today – October 1stMarketBeat's stock screener identified Medtronic, United Therapeutics, and Nexalin Technology as the top medical stocks to watch on October 1st, citing their highest dollar trading volume. The companies are described as device-based medical therapy, pulmonary hypertension treatment, and neurostimulation products, respectively.Quiver QuantitativeNexalin Technology shares surge on South America commercialization and manufacturing deal | NXL Stock NewsNexalin Technology shares rose 73.6% after announcing an exclusive distribution and local manufacturing agreement covering Brazil and other South American markets. The deal includes an initial purchase order, minimum revenue thresholds, and a path to recurring royalties, signaling a move toward commercial revenue.American Banking and Market NewsHead-To-Head Contrast: Nexalin Technology (NASDAQ:NXL) & Fresenius SE & Co. (OTCMKTS:FSNUY)Nexalin Technology and Fresenius SE & Co. are compared on analyst ratings, risk, profitability, and valuation. Fresenius beats Nexalin on 9 of 13 factors, with higher revenue ($25.87B vs $300K) and positive net margins, while Nexalin trades at a lower P/E but has a beta of 3.95.Ticker ReportShort Interest in Nexalin Technology, Inc. (NASDAQ:NXL) Declines By 96.0%Short interest in Nexalin Technology fell 96% to 13,667 shares as of August 31, down from 342,208 on August 15. Weiss Ratings raised the stock from a sell (e+) to a sell (d-) rating, and shares traded down 1% to $4.82. The company reported a loss of $0.11 per share, beating estimates.